Search results
Results from the WOW.Com Content Network
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, [8] which is used in the treatment of schizophrenia, bipolar mania, [9] bipolar depression, [10] and major depressive disorder. [6] It acts primarily as a D 3 and D 2 receptor partial agonist, with a preference for the D 3 ...
Vistaril (hydroxyzine) – an antihistamine for the treatment of itches and irritations, an antiemetic, as a weak analgesic, an opioid potentiator, and as an anxiolytic; Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo
Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder. Use of any antipsychotic is associated with reductions in brain tissue volumes, [ 6 ] [ 7 ] including white matter reduction, [ 8 ] an effect which is dose-dependent and time-dependent.
Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can impact daily functioning and behavior. Bipolar Disorder: 4 Types & What ...
The labeling information of the treatment, Cobenfy, does not include a warning about the risk of increased mortality in some elderly patients, unlike other commonly used drugs for the disorder ...
2024 was packed with health care innovations, from a new blood test detecting Alzheimer’s disease to deep brain stimulation reversing paralysis. Heading into the New Year, medical experts are ...
The wakefulness-promoting agent modafinil and its analogues (e.g., adrafinil, armodafinil) have been approved to treat narcolepsy and shift work sleep disorder. [7] These act as weak DRIs, [8] but this effect does not correlate with wakefulness-promoting effects, suggesting the effect is too weak to be of clinical significance. The conclusion ...
Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts are betting on a 2027 list that will include Novo Nordisk's blockbuster ...